Med Life S.A. enters the week caught between two compelling signals: one of the strongest forward earnings momentum profiles in European healthcare, and a founding family that has sold nearly every step of the way up.
The earnings story is genuinely striking. Forward EPS momentum ranks in the 85th percentile over 90 days and the 79th percentile over 30 days — numbers that suggest analysts have been steadily revising estimates higher as the business performs. Most notably, the 12-month forward EPS year-on-year growth rate ranks in the 98th percentile across the universe. That's a top-two-percentile growth signal. The stock's PE has eased to around 42x on a trailing basis, down roughly 2.5 points over the past month as the price dipped 4.5%, while EV/EBITDA ticked higher to just over 14x. The valuation is not cheap by any conventional measure, but the earnings trajectory is what the bulls are paying for — and so far the numbers have been supporting the thesis.
The analyst community, however, is not rushing to press the case. Three analysts cover the stock and all three rate it a hold. No recent changes have been filed. The dividend score ranks at 69 — decent but not a draw — and there is no meaningful near-term catalyst from that angle either. A rights issue from 2017 is the only entry in the dividend history, further suggesting the company has historically preferred to reinvest rather than distribute. The next scheduled earnings event falls in late August, giving investors a roughly 12-week wait for the next data point.
Where the article from earlier this week remains valid: the founder-led selling is the most persistent and legible signal in the stock. CEO Mihail Marcu sold 700,000 shares in January 2026 at RON 11.50 — essentially the current price level of RON 11.46. His brother Nicolae, on the Executive Board, has been a parallel seller across every major step up since early 2025. Together the Marcu family has disposed of well over 9 million shares across this rally. The pattern has not changed. The last reported insider trade is now roughly 131 days old, so the picture has not materially updated since then, but nothing in the interim data suggests the trend reversed. Net 90-day insider disposals remain around $3.9 million.
Ownership is otherwise notable for how concentrated it is. The top four shareholders — Mihaela-Gabriela Cristescu, Romanian pension fund NN, Mihail Marcu, and Nicolae Marcu — together hold roughly 50% of shares. MetLife Investment Management holds another 7.9%. Institutional depth beyond those five names is thin. Vanguard entities added a small number of shares as recently as April, but the increments are immaterial relative to the founder sales.
The lending market adds nothing urgent to the story right now. All available borrow data predates mid-2024 and should not be read as current. What that data does confirm, from the last available reading, is that the stock was essentially unloved by short sellers — availability was extremely loose and no meaningful short position had been established. The short score history, also stale from early 2024, was running around 30 out of 100, firmly in the low-conviction shorting range. Nothing in the price action — the stock is up nearly 70% from its July 2025 lows — suggests that dynamic has reversed.
The question heading into August earnings is whether the exceptional EPS momentum the factor scores are flagging will translate into a formal upgrade cycle — or whether the Street stays on the sidelines and the founders continue to define the marginal seller.
See the live data behind this article on ORTEX.
Open M on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
